Tapentadol Prolonged Release Reduces the Severe Chronic Ischaemic Pain and Improves the Quality of Life in Patients with Type 2 Diabetes.

about

Tapentadol Prolonged Release Reduces the Severe Chronic Ischaemic Pain and Improves the Quality of Life in Patients with Type 2 Diabetes.

Item

http://www.wikidata.org/entity/Q55395765

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Tapentadol Prolonged Release R ...... Patients with Type 2 Diabetes.

@en

Tapentadol Prolonged Release R ...... Patients with Type 2 Diabetes.

@nl

type

Item

label

Tapentadol Prolonged Release R ...... Patients with Type 2 Diabetes.

@en

Tapentadol Prolonged Release R ...... Patients with Type 2 Diabetes.

@nl

prefLabel

Tapentadol Prolonged Release R ...... Patients with Type 2 Diabetes.

@en

Tapentadol Prolonged Release R ...... Patients with Type 2 Diabetes.

@nl

P1476

Tapentadol Prolonged Release R ...... Patients with Type 2 Diabetes

@en

P2093

Alessandra De Bellis

http://www.w3.org/2001/XMLSchema#string

Anna Tedeschi

http://www.w3.org/2001/XMLSchema#string

Arianna Bernini

http://www.w3.org/2001/XMLSchema#string

Elisabetta Salutini

http://www.w3.org/2001/XMLSchema#string

Marco Perini

http://www.w3.org/2001/XMLSchema#string

P2860

Diabetic neuropathic pain: Physiopathology and treatment

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013

Burning through the pain: treatments for diabetic neuropathy.

Treating Painful Diabetic Peripheral Neuropathy: An Update.

Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial.

(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.

A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy

Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy?

Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy.

Population Pharmacokinetic Modeling of Tapentadol Extended Release (ER) in Healthy Subjects and Patients with Moderate or Severe Chronic Pain.

P304

1081792

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2018/1081792

http://www.w3.org/2001/XMLSchema#string

P478

2018

http://www.w3.org/2001/XMLSchema#string

P50

Roberto Anichini

Piergiorgio Francia

P577

2018-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29675431

http://www.w3.org/2001/XMLSchema#string

P921

chronic pain

quality of life

type-2 diabetes

P932

5838502

http://www.w3.org/2001/XMLSchema#string